ArticleGMS ophthalmology cases2026
A case of corneal epithelial downgrowth after penetrating keratoplasty treated by intracameral 5-fluorouracil injection and mitomycin C.
Article in GMS ophthalmology cases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Corneal epithelial downgrowth is an uncommon, yet potentially sight-threatening complication of intraocular surgery or trauma with poor prognosis. We hereby describe a case of epithelial downgrowth after penetrating keratoplasty which was treated by intracameral 5-fluorouracil injection. Case description: In 2019, penetrating keratoplasty was performed for a 69-year-old man with pseudophakic bullous keratopathy. Six months after penetrating keratoplasty, an endothelial opacity suspicious of epithelial downgrowth was noted. Two treatments of intracameral 5-fluorouracil injection were performed at the eighth and ninth month after penetrating keratoplasty, which allowed the epithelial downgrowth to become quiescent. A repeated penetrating keratoplasty with intracameral application of mitomycin C was subsequently performed without reactivation of the epithelial downgrowth. Conclusion: Intracameral 5-fluorouracil injection is effective in halting disease progression in epithelial downgrowth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.